HUE052857T2 - Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszerei - Google Patents
Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszereiInfo
- Publication number
- HUE052857T2 HUE052857T2 HUE15838800A HUE15838800A HUE052857T2 HU E052857 T2 HUE052857 T2 HU E052857T2 HU E15838800 A HUE15838800 A HU E15838800A HU E15838800 A HUE15838800 A HU E15838800A HU E052857 T2 HUE052857 T2 HU E052857T2
- Authority
- HU
- Hungary
- Prior art keywords
- inhibitor
- levodopa
- administration
- pharmaceutical compositions
- dopamine decarboxylase
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 239000003954 decarboxylase inhibitor Substances 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1451034A SE538425C2 (en) | 2014-09-04 | 2014-09-04 | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
SE1550344 | 2015-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE052857T2 true HUE052857T2 (hu) | 2021-05-28 |
Family
ID=55440194
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE15838800A HUE052857T2 (hu) | 2014-09-04 | 2015-09-04 | Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszerei |
HUE20200070A HUE066097T2 (hu) | 2014-09-04 | 2015-09-04 | Levodopát, karbidopát és entakapont tartalmazó gyógyászati készítmények |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE20200070A HUE066097T2 (hu) | 2014-09-04 | 2015-09-04 | Levodopát, karbidopát és entakapont tartalmazó gyógyászati készítmények |
Country Status (16)
Country | Link |
---|---|
US (4) | US10071069B2 (hu) |
EP (3) | EP3782617B1 (hu) |
JP (2) | JP6622310B2 (hu) |
CN (1) | CN107072973A (hu) |
AU (3) | AU2015312430B2 (hu) |
CA (2) | CA2959307C (hu) |
DK (2) | DK3782617T3 (hu) |
ES (2) | ES2973289T3 (hu) |
FI (1) | FI3782617T3 (hu) |
HR (2) | HRP20240314T1 (hu) |
HU (2) | HUE052857T2 (hu) |
PL (2) | PL3188725T3 (hu) |
PT (2) | PT3782617T (hu) |
RS (1) | RS65337B1 (hu) |
SI (2) | SI3782617T1 (hu) |
WO (1) | WO2016036308A1 (hu) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6622310B2 (ja) | 2014-09-04 | 2019-12-18 | ロブソル・ファーマシューティカルズ・アクチボラグLobsor Pharmaceuticals Aktiebolag | レボドパ、ドーパミン脱炭酸酵素阻害薬およびcomt阻害薬を含む医薬組成物ならびにその投与方法 |
WO2016083863A1 (en) * | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
EP3291872A4 (en) | 2015-05-06 | 2019-02-13 | SynAgile Corporation | PHARMACEUTICAL SUSPENSIONS WITH ACTIVE SUBSTANCES, DEVICES FOR THEIR ADMINISTRATION AND METHOD FOR THEIR USE |
WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
CN109310658A (zh) * | 2016-04-11 | 2019-02-05 | 堪培拉大学 | 包含左旋多巴、抗氧化剂和水性载体的眼科组合物 |
EP3487479A1 (en) * | 2016-07-20 | 2019-05-29 | AbbVie Inc. | Levodopa and carbidopa intestinal gel and methods of use |
EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
US10780168B2 (en) * | 2017-02-13 | 2020-09-22 | Bayer Animal Health Gmbh | Liquid composition containing pradofloxacin |
WO2019129120A1 (en) * | 2017-12-28 | 2019-07-04 | Rpxds Co., Ltd | Tolcapone for prevention and/or treatment of obesity and related metabolic diseases |
SG11202009215PA (en) * | 2018-03-23 | 2020-10-29 | Lobsor Pharmaceuticals Ab | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
EP3593819A1 (en) | 2018-07-10 | 2020-01-15 | Medday Pharmaceuticals | Compositions for therapeutic uses containing 5-htp and carbidopa |
JP7506371B2 (ja) | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | ドーパミン減少抑制剤 |
CN111643493B (zh) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | 一种高浓度左旋多巴制剂及其制备方法及其应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
CN1329487A (zh) * | 1998-11-10 | 2002-01-02 | 特瓦制药工业有限公司 | 包含l-多巴乙酯的可分散组合物 |
FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
US20100221321A1 (en) | 2003-02-27 | 2010-09-02 | Innercap Technologies, Inc. | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions |
CN1845728B (zh) * | 2003-08-29 | 2013-06-19 | 转化医药公司 | 包含左旋多巴和卡比多巴的药物组合物 |
DE602004031134D1 (de) | 2003-08-29 | 2011-03-03 | Transform Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa |
WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
JP2009543761A (ja) | 2006-05-31 | 2009-12-10 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | レボドパ/カルビドパの長期間24時間腸内投与 |
WO2008053297A2 (en) | 2006-10-30 | 2008-05-08 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
US8709485B2 (en) | 2008-02-06 | 2014-04-29 | Wockhardt Limited | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
US20130253056A1 (en) * | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
RU2559083C9 (ru) * | 2009-05-19 | 2016-01-20 | Неуродерм Лтд | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
MX348225B (es) | 2010-11-15 | 2017-05-31 | Neuroderm Ltd | Administracion continua de levodopa, inhibidores de dopa decarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para la misma. |
WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
KR102209353B1 (ko) | 2013-03-13 | 2021-01-29 | 뉴로덤 엘티디 | 파킨슨 병 치료 방법 |
SE538425C2 (en) | 2014-09-04 | 2016-06-21 | Lobsor Pharmaceuticals Ab | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
JP6622310B2 (ja) | 2014-09-04 | 2019-12-18 | ロブソル・ファーマシューティカルズ・アクチボラグLobsor Pharmaceuticals Aktiebolag | レボドパ、ドーパミン脱炭酸酵素阻害薬およびcomt阻害薬を含む医薬組成物ならびにその投与方法 |
WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
-
2015
- 2015-09-04 JP JP2017533154A patent/JP6622310B2/ja active Active
- 2015-09-04 SI SI201531992T patent/SI3782617T1/sl unknown
- 2015-09-04 AU AU2015312430A patent/AU2015312430B2/en active Active
- 2015-09-04 ES ES20200070T patent/ES2973289T3/es active Active
- 2015-09-04 DK DK20200070.9T patent/DK3782617T3/da active
- 2015-09-04 CA CA2959307A patent/CA2959307C/en active Active
- 2015-09-04 HU HUE15838800A patent/HUE052857T2/hu unknown
- 2015-09-04 WO PCT/SE2015/050939 patent/WO2016036308A1/en active Application Filing
- 2015-09-04 EP EP20200070.9A patent/EP3782617B1/en active Active
- 2015-09-04 HR HRP20240314TT patent/HRP20240314T1/hr unknown
- 2015-09-04 SI SI201531474T patent/SI3188725T1/sl unknown
- 2015-09-04 DK DK15838800.9T patent/DK3188725T3/da active
- 2015-09-04 PT PT202000709T patent/PT3782617T/pt unknown
- 2015-09-04 PL PL15838800T patent/PL3188725T3/pl unknown
- 2015-09-04 PL PL20200070.9T patent/PL3782617T3/pl unknown
- 2015-09-04 HU HUE20200070A patent/HUE066097T2/hu unknown
- 2015-09-04 ES ES15838800T patent/ES2844500T3/es active Active
- 2015-09-04 CA CA3175785A patent/CA3175785A1/en active Pending
- 2015-09-04 EP EP15838800.9A patent/EP3188725B1/en active Active
- 2015-09-04 CN CN201580050984.7A patent/CN107072973A/zh active Pending
- 2015-09-04 RS RS20240276A patent/RS65337B1/sr unknown
- 2015-09-04 US US15/507,959 patent/US10071069B2/en active Active
- 2015-09-04 FI FIEP20200070.9T patent/FI3782617T3/fi not_active Application Discontinuation
- 2015-09-04 PT PT158388009T patent/PT3188725T/pt unknown
- 2015-09-04 EP EP23219005.8A patent/EP4356907A1/en active Pending
-
2018
- 2018-08-03 US US16/054,392 patent/US10786472B2/en active Active
-
2019
- 2019-11-21 JP JP2019210309A patent/JP6889231B2/ja active Active
-
2020
- 2020-08-13 US US16/992,824 patent/US11413262B2/en active Active
- 2020-09-23 AU AU2020239682A patent/AU2020239682B2/en active Active
-
2021
- 2021-01-07 HR HRP20210025TT patent/HRP20210025T1/hr unknown
-
2022
- 2022-01-18 AU AU2022200291A patent/AU2022200291B2/en active Active
- 2022-06-07 US US17/834,839 patent/US20220362193A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3188725T3 (pl) | Kompozycje farmaceutyczne zawierające lewodopę, inhibitor dekarboksylazy dopaminy i inhibitor comt oraz sposób ich podawania | |
IL260025A (en) | A drug for the treatment of influenza characterized by the combination of a cap-dependent endonuclease inhibitor with an anti-influenza drug | |
HK1256997A1 (zh) | Tyk2抑制劑及其用途 | |
HK1248690A1 (zh) | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 | |
HK1251466A1 (zh) | 包含pi3k抑制劑和hdac抑制劑的組合物 | |
ZA201803485B (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
IL247668B (en) | Preparations that include dopa decarboxylase inhibitors | |
RS62271B1 (sr) | Inhibitori 3-fosfoglicerat dehidrogenaze i njihova upotreba | |
EP3426244C0 (en) | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND THEIR USES | |
IL258513B (en) | History of quinoxaline and pyridopyrazine as pi3k inhibitors in the cell | |
IL247921A0 (en) | Glutaminase inhibitor compounds, preparations containing them and their uses | |
EP3771709C0 (en) | CREATINE PRODRUGS, COMPOSITIONS CONTAINING THEM AND METHODS OF USE THEREOF | |
EP3272742A4 (en) | Histone deacetylase inhibitor, and preparation method and use thereof | |
IL274701A (en) | Promote drugs, compositions and methods of their use | |
IL252752A0 (en) | Pharmaceutical preparations containing a combination of pyridazine and egfr inhibitor | |
IL251162A0 (en) | Monoamine oxidase-B inhibitors and rehabilitation | |
HK1244224B (zh) | Mek抑制劑的藥物組合物及其製備方法 |